ProShare Advisors’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $51K | Sell |
36,704
-9,570
| -21% | -$13.2K | ﹤0.01% | 1784 |
|
|
2025
Q4 | $74.5K | Buy |
46,274
+3,524
| +8% | +$7.38K | ﹤0.01% | 1908 |
|
|
2025
Q3 | $117K | Sell |
42,750
-8,516
| -17% | -$28.3K | ﹤0.01% | 1816 |
|
|
2025
Q2 | $187K | Buy |
51,266
+4,388
| +9% | +$12.1K | ﹤0.01% | 1742 |
|
|
2025
Q1 | $90K | Sell |
46,878
-11,707
| -20% | -$23.9K | ﹤0.01% | 1856 |
|
|
2024
Q4 | $111K | Buy |
58,585
+19,277
| +49% | +$33.5K | ﹤0.01% | 2055 |
|
|
2024
Q3 | $51.9K | Buy |
+39,308
| New | +$52.5K | ﹤0.01% | 1975 |
|
|
2022
Q4 | – | Sell |
-15,465
| Closed | -$5K | – | 1852 |
|
|
2022
Q3 | $5K | Buy |
15,465
+1,172
| +8% | +$460 | ﹤0.01% | 1745 |
|
|
2022
Q2 | $5K | Sell |
14,293
-36,514
| -72% | -$15.3K | ﹤0.01% | 1788 |
|
|
2022
Q1 | $36K | Sell |
50,807
-11,934
| -19% | -$25.5K | ﹤0.01% | 2137 |
|
|
2021
Q4 | $142K | Buy |
62,741
+3,107
| +5% | +$8.47K | ﹤0.01% | 2140 |
|
|
2021
Q3 | $172K | Sell |
59,634
-10,588
| -15% | -$30.2K | ﹤0.01% | 1821 |
|
|
2021
Q2 | $266K | Buy |
70,222
+10,685
| +18% | +$36K | ﹤0.01% | 1968 |
|
|
2021
Q1 | $202K | Buy |
59,537
+5,501
| +10% | +$19.8K | ﹤0.01% | 2037 |
|
|
2020
Q4 | $151K | Buy |
54,036
+13,388
| +33% | +$39.1K | ﹤0.01% | 1920 |
|
|
2020
Q3 | $102K | Buy |
40,648
+348
| +0.9% | +$3.05K | ﹤0.01% | 1521 |
|
|
2020
Q2 | $547K | Buy |
40,300
+17,001
| +73% | +$176K | ﹤0.01% | 911 |
|
|
2020
Q1 | $177K | Sell |
23,299
-18,426
| -44% | -$143K | ﹤0.01% | 1027 |
|
|
2019
Q4 | $264K | Sell |
41,725
-3,901
| -9% | -$18.5K | ﹤0.01% | 1423 |
|
|
2019
Q3 | $179K | Buy |
45,626
+2,131
| +5% | +$9.13K | ﹤0.01% | 1461 |
|
|
2019
Q2 | $211K | Sell |
43,495
-5,351
| -11% | -$30.4K | ﹤0.01% | 1417 |
|
|
2019
Q1 | $400K | Buy |
48,846
+20,497
| +72% | +$141K | ﹤0.01% | 1120 |
|
|
2018
Q4 | $157K | Sell |
28,349
-1,079
| -4% | -$8.44K | ﹤0.01% | 1416 |
|
|
2018
Q3 | $260K | Sell |
29,428
-1,120
| -4% | -$10K | ﹤0.01% | 1446 |
|
|
2018
Q2 | $305K | Buy |
30,548
+2,972
| +11% | +$29.8K | ﹤0.01% | 1375 |
|
|
2018
Q1 | $263K | Sell |
27,576
-4,534
| -14% | -$63.4K | ﹤0.01% | 1396 |
|
|
2017
Q4 | $477K | Buy |
32,110
+2,478
| +8% | +$41.1K | ﹤0.01% | 1157 |
|
|
2017
Q3 | $583K | Buy |
29,632
+6,424
| +28% | +$98.8K | 0.01% | 898 |
|
|
2017
Q2 | $333K | Sell |
23,208
-1,385
| -6% | -$17.6K | ﹤0.01% | 1113 |
|
|
2017
Q1 | $226K | Sell |
24,593
-6,499
| -21% | -$63.4K | ﹤0.01% | 1395 |
|
|
2016
Q4 | $324K | Buy |
31,092
+3,573
| +13% | +$30.8K | ﹤0.01% | 1316 |
|
|
2016
Q3 | $249K | Sell |
27,519
-5,146
| -16% | -$43.7K | ﹤0.01% | 1232 |
|
|
2016
Q2 | $244K | Buy |
32,665
+831
| +3% | +$7.25K | ﹤0.01% | 1310 |
|
|
2016
Q1 | $287K | Buy |
31,834
+3,429
| +12% | +$27.8K | ﹤0.01% | 1225 |
|
|
2015
Q4 | $367K | Buy |
28,405
+4,052
| +17% | +$41.3K | ﹤0.01% | 1189 |
|
|
2015
Q3 | $235K | Sell |
24,353
-1,766
| -7% | -$16.2K | ﹤0.01% | 1240 |
|
|
2015
Q2 | $269K | Buy |
26,119
+8,217
| +46% | +$70.1K | ﹤0.01% | 1352 |
|
|
2015
Q1 | $199K | Buy |
17,902
+2,750
| +18% | +$29.3K | ﹤0.01% | 1724 |
|
|
2014
Q4 | $176K | Buy |
+15,152
| New | +$217K | ﹤0.01% | 1764 |
|
Other funds holding AKBA
VCM
VPM
ProShare Advisors's AKBA Position: Q1 2026 in Review
ProShare Advisors reduced its Akebia Therapeutics (AKBA) stake by 21% in Q1 2026, selling an estimated $13.2K and leaving 36,704 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #1784.
ProShare Advisors first reported a position in AKBA in Q4 2014 and has held it in 39 quarters since. The position peaked at $583K in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- ProShare Advisors held 36,704 shares of Akebia Therapeutics worth $51K as of Q1 2026.
- ProShare Advisors sold 9,570 Akebia Therapeutics shares in Q1 2026, an estimated $13.2K.
- Akebia Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1784 holding.
- ProShare Advisors first reported a position in Akebia Therapeutics in Q4 2014 and has held it in 39 quarters since.
- ProShare Advisors's Akebia Therapeutics position peaked at $583K in Q3 2017.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.